At the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, held from 31 May to 3 June in Chicago, Illinois, updated efficacy and safety data from the randomised, double-blind, placebo-controlled Phase III AMPLITUDE (NCT04497844) clinical …

Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 …

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in …

Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” …

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2024. “Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and …

New Brunswick: Johnson & Johnson has announced that William N. (Bill) Hait, M.D., Ph.D., will retire from his position as Executive Vice President, Chief External Innovation and Medical Officer, in September of this year. Since joining Johnson & …

Breaking News Innovative Medicine sales were up 1%, while COVID-19 Vaccine sales were down 97%. 05.20.24 Johnson & Johnson 1Q Revenues: $21.4 billion (+2%) 1Q Earnings: $5.4 billion (loss of $491 million 1Q23) Comments: Innovative Medicine sales were …

In the section titled "Full-Year 2024 Guidance", in the table, row titled "Operational Sales2,5/ Mid-point", the numbers for the April 2024 column should read: $88.7B – $89.1B / $88.9B (instead of: $88.7B – $89.1B / $88.0B). …

Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Call Transcript January 23, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.29, expectations were $2.27. Johnson & Johnson isn’t one of the 30 most popular stocks among hedge …

Adjusted earnings per share for the quarter came in at $2.29, surpassing expectations by a narrow margin. For the full year, Johnson & Johnson reported sales of $85.2bn, representing a 6.5% growth rate. However, full-year earnings per share decreased …